In a major disappointment to Novartis (NYSE:NVS), the U.S. Supreme Court rejected the company’s request to block a Federal Circuit mandate that would allow the generic versions of its blockbuster multiple sclerosis drug Gilenya, Reuters reported. Gilenya is one of Novratis’ top-selling drug and generated sales of $2.8 billion in 2021. In late September, the U.S. Supreme Court’s Chief Justice John Roberts agreed to temporarily stay the mandate from the US Court of Appeals for the Federal Circuit regarding the validity of a key patent for Gilenya. With the U.S.
https://www.tipranks.com/news/the-u-s-supreme-court-rejects-novartis-nysenvs-bid-to-block-gilenya-generics?utm_source=advfn.com&utm_medium=referral
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023 Click aqui para mais gráficos Novartis.